← Back to Search

Molecular and Structural Imaging for Alzheimer's Disease

N/A
Recruiting
Led By Jennifer Whitwell, Ph.D.
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language
All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA)
Must not have
Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded
Women that are pregnant or post-partum and breast-feeding will be excluded
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial looks at amyloid and tau in the brains of people with atypical Alzheimer's to see how it changes over time.

Who is the study for?
This study is for adults over 21 with Atypical Alzheimer's Disease, specifically those diagnosed with Logopenic Aphasia or Posterior Cortical Atrophy. Participants must have a person to report on their functioning and speak English as their primary language. They can't join if they've had strokes, tumors, severe memory issues early on, other neurodegenerative diseases, very poor vision, are pregnant/breastfeeding, or have MRI contraindications.
What is being tested?
The trial is using advanced brain imaging techniques (F-18 AV 1451 and C-11 PiB) to investigate the presence of amyloid and tau proteins in patients' brains. It aims to see how these protein levels change over one year in individuals with atypical forms of Alzheimer's disease.
What are the potential side effects?
While the document doesn’t specify side effects related to F-18 AV 1451 and C-11 PiB imaging agents used in PET scans directly, common side effects from such procedures may include discomfort at injection site or allergic reactions; however individual experiences may vary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have trouble finding the right words and forming sentences.
Select...
I have Alzheimer's with worsening memory loss or specific symptoms like LPA or PCA.
Select...
I am over 21 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any other neurodegenerative disorders like frontotemporal dementia.
Select...
I am not pregnant, post-partum, or breastfeeding.
Select...
I can have a tau-PET scan and don't have Cowden, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich, or Down's syndrome.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Tau PET Scan, F-18 AV 1451Experimental Treatment2 Interventions
All subjects will receive two Tau PET scans during this study.
Group II: PiB PET Scan, C-11 PiBExperimental Treatment2 Interventions
All subjects will receive two PiB PET scans during this study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
C-11 PiB
2010
Completed Phase 1
~240

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,342 Previous Clinical Trials
3,062,272 Total Patients Enrolled
2 Trials studying Amnesia
277 Patients Enrolled for Amnesia
National Institute on Aging (NIA)NIH
1,789 Previous Clinical Trials
28,188,272 Total Patients Enrolled
Jennifer Whitwell, Ph.D.Principal Investigator - Mayo Clinic
Mayo Clinic

Media Library

C-11 PiB Clinical Trial Eligibility Overview. Trial Name: NCT02740634 — N/A
Amnesia Research Study Groups: Tau PET Scan, F-18 AV 1451, PiB PET Scan, C-11 PiB
Amnesia Clinical Trial 2023: C-11 PiB Highlights & Side Effects. Trial Name: NCT02740634 — N/A
C-11 PiB 2023 Treatment Timeline for Medical Study. Trial Name: NCT02740634 — N/A
~8 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top